| 29.5365 0.334 (1.14%) | 05-15 16:10 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 35.44 | 1-year : | 41.4 |
| Resists | First : | 30.34 | Second : | 35.44 |
| Pivot price | 29.81 |
|||
| Supports | First : | 28.18 | Second : | 26.85 |
| MAs | MA(5) : | 29.52 |
MA(20) : | 29.67 |
| MA(100) : | 31.12 |
MA(250) : | 31.55 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 13.8 |
D(3) : | 27.6 |
| RSI | RSI(14): 46.2 |
|||
| 52-week | High : | 34.43 | Low : | 26.85 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ HART ] has closed above bottom band by 28.9%. Bollinger Bands are 27.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 29.58 - 29.74 | 29.74 - 29.9 |
| Low: | 28.72 - 28.94 | 28.94 - 29.14 |
| Close: | 29.22 - 29.54 | 29.54 - 29.83 |
The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the index, which was developed by IndexIQ LLC with Candriam Belgium S.A. acting as index consultant to IndexIQ. The index includes securities of large-, mid- and small-capitalization companies that trade in the U.S. and foreign markets, including emerging markets other than China, Egypt, India, Kuwait, Pakistan, Qatar, Saudi Arabia and United Arab Emirates.
Tue, 22 Apr 2025
Trend Tracker for (HART) - news.stocktradersdaily.com
Fri, 31 Jan 2025
(HART) Long Term Investment Analysis - news.stocktradersdaily.com
Tue, 10 Sep 2024
The battle against heart disease and how to invest in it - Moneyweek
Fri, 01 Mar 2024
Healthy 'HART' ETF: A Fresh Spin on ESG Funds - ETF.com
Thu, 28 Dec 2023
Artificial intelligence promises to transform diagnosis of heart disease - Financial Times
Tue, 19 Dec 2023
The 10 Best Healthcare & Biotech ETFs to Buy Now - TheStreet
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|